MeSH term
Frequency | Condition_Probility | Alleles | 9 | 0.0 |
Blotting, Southern | 6 | 0.0 |
CpG Islands/genetics | 2 | 1.0 |
Fragile X Syndrome/diagnosis/*genetics | 2 | 15.0 |
Genetic Screening/*methods | 2 | 1.0 |
Humans | 43 | 0.0 |
Male | 30 | 0.0 |
Molecular Sequence Data | 13 | 0.0 |
Mutation/*genetics | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 33 | 0.0 |
Sensitivity and Specificity | 2 | 0.0 |
Trinucleotide Repeat Expansion/genetics | 2 | 5.0 |
Chromosome Fragile Sites | 12 | 8.0 |
Chromosome Fragility | 5 | 8.0 |
Fragile X Syndrome/*genetics | 17 | 10.0 |
Genetic Screening | 4 | 0.0 |
*Linkage (Genetics) | 4 | 0.0 |
Mutation | 5 | 0.0 |
*Nuclear Proteins | 7 | 0.0 |
Phenotype | 4 | 0.0 |
Proteins/*genetics | 5 | 0.0 |
*Trans-Activators | 7 | 1.0 |
*X Chromosome | 15 | 1.0 |
Cells, Cultured | 2 | 0.0 |
Chromosome Fragility/*genetics | 3 | 17.0 |
Genetic Markers | 4 | 0.0 |
Heterozygote | 3 | 0.0 |
In Situ Hybridization, Fluorescence | 3 | 0.0 |
Polymerase Chain Reaction | 7 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 9 | 0.0 |
Sequence Tagged Sites | 2 | 0.0 |
Time Factors | 2 | 0.0 |
DNA/genetics | 2 | 0.0 |
Gene Frequency | 2 | 0.0 |
Microsatellite Repeats | 3 | 0.0 |
Nerve Tissue Proteins/*genetics | 4 | 0.0 |
*RNA-Binding Proteins | 9 | 2.0 |
Trinucleotide Repeats/genetics | 2 | 3.0 |
Chromosome Disorders | 2 | 0.0 |
Fragile X Syndrome/genetics | 4 | 12.0 |
Mental Retardation/genetics | 5 | 4.0 |
X Chromosome/genetics | 3 | 1.0 |
Adolescent | 8 | 0.0 |
Adult | 9 | 0.0 |
Child | 11 | 0.0 |
Child, Preschool | 9 | 0.0 |
Female | 25 | 0.0 |
Mothers | 2 | 2.0 |
Prevalence | 2 | 0.0 |
Brazil | 2 | 0.0 |
Mental Retardation/*genetics | 10 | 4.0 |
Nerve Tissue Proteins/genetics | 4 | 1.0 |
Trinucleotide Repeats | 3 | 2.0 |
Amino Acid Sequence | 4 | 0.0 |
Trinucleotide Repeats/*genetics | 3 | 3.0 |
English Abstract | 2 | 0.0 |
Chromosome Mapping | 9 | 0.0 |
Genetic Diseases, Inborn/genetics | 2 | 4.0 |
Infant, Newborn | 4 | 0.0 |
Polymerase Chain Reaction/*methods | 2 | 0.0 |
Sex Factors | 2 | 0.0 |
China | 3 | 0.0 |
DNA/*genetics | 2 | 0.0 |
*Mutation | 2 | 0.0 |
*Chromosome Fragility | 8 | 6.0 |
Cloning, Molecular | 4 | 0.0 |
England | 2 | 1.0 |
*Trinucleotide Repeats | 6 | 5.0 |
Learning Disorders/*genetics | 2 | 20.0 |
Developmental Disabilities/genetics | 2 | 10.0 |
Fragile X Syndrome/*genetics/pathology/psychology | 2 | 100.0 |
Infant | 4 | 0.0 |
Pedigree | 14 | 0.0 |
Haplotypes | 2 | 0.0 |
Base Sequence | 10 | 0.0 |
DNA Primers | 3 | 0.0 |
Finland | 2 | 0.0 |
Polymorphism, Genetic | 3 | 0.0 |
Brain/metabolism | 2 | 0.0 |
Dinucleoside Phosphates | 2 | 11.0 |
*Repetitive Sequences, Nucleic Acid | 6 | 1.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Gene Library | 2 | 0.0 |
Fragile X Syndrome/*epidemiology/genetics | 2 | 66.0 |
X Chromosome | 2 | 0.0 |
Developmental Disabilities/*genetics | 2 | 11.0 |
Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Genetic Diseases, Inborn/*genetics | 2 | 3.0 |
Middle Aged | 3 | 0.0 |
Methylation | 3 | 0.0 |
Restriction Mapping | 2 | 0.0 |
X Chromosome/*ultrastructure | 2 | 8.0 |
